HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Heparin-binding protein (HBP) in critically ill patients with influenza A(H1N1) infection.

Abstract
Heparin-binding protein (HBP) is an inducer of vascular endothelial leakage in severe infections. Fluid accumulation into alveoli is a general finding in acute respiratory distress syndrome (ARDS). Severe acute respiratory failure with ARDS is a complication of influenza A(H1N1) infection. Accordingly, we studied the HBP levels in critically ill patients with infection of influenza A(H1N1).Critically ill patients in four intensive care units (ICUs) with polymerase chain reaction (PCR) confirmed infection of influenza A(H1N1) were prospectively evaluated. We collected clinical data and blood samples at ICU admission and on day 2. Twenty-nine patients participated in the study. Compared with normal plasma levels, the HBP concentrations were highly elevated at baseline and at day 2: 98 ng/mL (62-183 ng/mL) and 93 ng/mL (62-271 ng/mL) (p 0.876), respectively. HBP concentrations were correlated with the lowest ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen (PF ratio) during the ICU stay (rho = -0.321, p <0.05). In patients with and without invasive mechanical ventilation, the baseline HBP levels were 152 ng/mL (72-237 ng/mL) and 83 ng/mL (58-108 ng/mL) (p 0.088), respectively. The respective values at day 2 were 223 ng/mL (89-415 ng/mL) and 81 ng/mL (55-97 ng/mL) (p <0.05). The patients with septic shock/severe sepsis (compared with those without) did not have statistically significant differences in HBP concentrations at baseline or day 2. HBP concentrations are markedly elevated in all critically ill patients with influenza A(H1N1) infection. The increase in HBP concentrations seems to be associated with more pronounced respiratory dysfunction.
AuthorsK-M Kaukonen, R Linko, H Herwald, L Lindbom, E Ruokonen, T Ala-Kokko, V Pettilä
JournalClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Clin Microbiol Infect) Vol. 19 Issue 12 Pg. 1122-8 (Dec 2013) ISSN: 1469-0691 [Electronic] France
PMID23402373 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.
Chemical References
  • Antimicrobial Cationic Peptides
  • Antiviral Agents
  • Blood Proteins
  • Carrier Proteins
  • cationic antimicrobial protein CAP 37, human
  • Oseltamivir
Topics
  • Adult
  • Antimicrobial Cationic Peptides (blood)
  • Antiviral Agents (therapeutic use)
  • Blood Proteins
  • Carrier Proteins (blood)
  • Critical Illness
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype (genetics)
  • Influenza, Human (blood, complications)
  • Intensive Care Units
  • Male
  • Middle Aged
  • Oseltamivir (therapeutic use)
  • Polymerase Chain Reaction
  • Prospective Studies
  • Respiration, Artificial (adverse effects)
  • Respiratory Distress Syndrome, Adult (blood, complications, virology)
  • Respiratory Insufficiency (blood, complications, virology)
  • Shock, Septic (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: